Why the study?
Does thrombolytic therapy improve haemodynamics or mortality compared to anticoagulants alone in patients with massive pulmonary embolism?
Does thrombolytic therapy improve haemodynamics or mortality compared to anticoagulants alone in patients with massive pulmonary embolism?
Thrombolytic therapy improves hemodynamics in massive pulmonary embolism compared to anticoagulation alone, though mortality benefits remain unproven due to small study sizes.
May support thrombolysis for hemodynamic stabilization in massive PE; leaves open mortality benefit pending larger trials.
In massive pulmonary embolism where there may be evidence of right ventricular dysfunction and acute pulmonary hypertension, anticoagulation therapy alone may prove inadequate. In such situations use of thrombolytic agents produces an improvement in haemodynamics compared to anticoagulants alone, although studies to date have been too small to address the issue of mortality benefit. It would appear that all age groups gain benefit from the use of thrombolytics. Studies that have compared thrombolytic agents and anticoagulants are discussed. In addition, the issues of the choice of thrombolytic agent and the different modes of delivery of therapy are addressed.
No takes yet. Share an insight, caveat, or question.
More et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: